Search
Pulmonary Fibrosis Paid Clinical Trials in Indiana
A listing of 7 Pulmonary Fibrosis clinical trials in Indiana actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 7 of 7
The state of Indiana currently has 7 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Overweight Trials
Recruiting
Overweight trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Overweight
Featured Trial
Low back pain Trials
Recruiting
Low back pain trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Low back pain
Featured Trial
55+ Obesity and Cardiovascular Disease Clinical Study
Recruiting
Diagnosed with cardiovascular disease? Join our local overweight with cardiovascular issues clinical trial. Every 34 seconds, someone in the US dies of cardiovascular disease. Wonder how you could help? If you’re eligible for our CVD clinical trial, you could receive up to $1500.
Conditions:
Obesity
Overweight and Obesity
Cardiovascular Disease
Cardiovascular Diseases
Cardiovascular Health
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/19/2024
Locations: IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine, Muncie, Indiana
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/13/2024
Locations: Local Institution - 0190, Indianapolis, Indiana
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/13/2024
Locations: Local Institution - 0441, Indianapolis, Indiana
Conditions: Progressive Pulmonary Fibrosis
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
06/12/2024
Locations: Indiana University Health, Indianapolis, Indiana
Conditions: Idiopathic Pulmonary Fibrosis
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/11/2024
Locations: IU Health Advanced Heart and Lung Care, Indianapolis, Indiana
Conditions: Idiopathic Pulmonary Fibrosis
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/04/2024
Locations: Community Health Network, Indianapolis, Indiana
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine, Muncie, Indiana
Conditions: Idiopathic Pulmonary Fibrosis
1 - 7 of 7